Prescription drug · BLA
Humira (adalimumab) NDC 0074-0243
Kit · AbbVie Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0074-0243-02 | 00074024302 | 2 KIT in 1 CARTON (0074-0243-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE * 1 mL in 1 PACKETMarketed from Nov 23, 2015 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Humira
- Generic name (nonproprietary)
- adalimumab
- Dosage form
- Kit
- Labeler
- AbbVie Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125057
- Marketing start
- Listing expires
- Identifiers
- Product ID 0074-0243_8bf84b15-6763-41cf-bfa4-bcee9ad4ef9aSPL ID 8bf84b15-6763-41cf-bfa4-bcee9ad4ef9aSPL set ID 608d4f0d-b19f-46d3-749a-7159aa5f933dRxCUI 727703, 727705, 763564, 763565, 797544, 825169, 825170, 1594352, 1594357, 1594358, 1655726, 1655728, 1656703, 1726844, 1726846, 1801277, 1801278, 1855523, 1855524, 1855526, 1855527, 1872979, 1872980, 1872983, 1872984, 1872985, 1872986, 1873086, 1873087, 1921009, 1921010, 1921016, 1921017, 1921238, 1921240, 1921244, 1921245, 1921467, 1921468, 2531133, 2531134
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N400074024302followed by a unit qualifier and the quantityPackage 00074-0243-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4…
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 125057
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-0817 |
| Humiraadalimumab | — | Kit | A-S Medication Solutions | 50090-4487 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-2540 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-0554 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-0616 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-3799 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-0124 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-4339 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-1539 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-124 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-616 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-243 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-554 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-817 |